Advertisement

Neurological Sciences

, Volume 39, Issue 6, pp 1065–1072 | Cite as

Association between two SCN1A polymorphisms and resistance to sodium channel blocking AEDs: a meta-analysis

  • Yi Bao
  • Xinzhu Liu
  • Zheng Xiao
Original Article

Abstract

Sodium channel blocking antiepileptic drugs (SCB-AEDs) are common effective medications available for epilepsy. However, not all patients respond to this regimen and drug resistance is frequently encountered. Rs2298771(c.3184A > G/p.Thr1067Ala) and rs3812718(IVS5N +5G > A) polymorphisms are two of the most common polymorphisms in the SCN1A gene, which is closely related to resistance to SCB-AEDs. Therefore, we have conducted a meta-analysis to investigate the contribution of the two polymorphisms to resistance of SCB-AEDs. The PubMed, Embase, MEDLINE, and Cochrane Library databases were searched up to September 2017, for studies on the association of SCN1A polymorphisms with resistance to SCB-AEDs. A fixed-effects or random-effects model was used to calculate the pooled odds ratios based on the results from the heterogeneity tests. A total of eight studies were eligible for the pooled analysis, of which eight studies included SCN1A rs3812718 polymorphism and four studies included SCN1A rs2298771 polymorphism. The results showed that SCN1A rs2298771 polymorphism was significantly associated with resistance to SCB-AEDs. (A vs. G: OR = 0.76, 95% CI 0.61–0.95, P = 0.02; AA vs. AG + GG: OR = 0.71, 95% CI 0.54–0.94, P = 0.022). However, no association was observed between SCN1A rs3812718 polymorphism and resistance to SCB-AEDs. Our results indicate that the A-allele of SCN1A rs2298771 polymorphism, especially AA genotype, may play an important role in responsiveness to SCB-AEDs, while SCN1A rs3812718 polymorphism is not associated with SCB-AEDs.

Keywords

Antiepileptic drugs Resistance Polymorphisms SCN1A Meta-analysis 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (grant number 81071040, 81471320).

Compliance with ethical standards

Conflict of interest

None of the authors has any conflicts of interest to disclose.

References

  1. 1.
    Fisher RS, Boas WE, Blume W, Elger C, Genton P, Lee P, Engel J (2005) Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46(4):470–472CrossRefPubMedGoogle Scholar
  2. 2.
    Brodie MJ (2016) Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide. Curr Neurol Neurosci Rep 16(9):82CrossRefPubMedGoogle Scholar
  3. 3.
    Sisodiya SM, Marini C (2009) Genetics of antiepileptic drug resistance. Curr Opin Neurol 22(2):150–156CrossRefPubMedGoogle Scholar
  4. 4.
    Manna I, Labate A, Borzì G, Mumoli L, Cavalli SM, Sturniolo M, Quattrone A, Gambardella A (2016) An SNP site in pri-miR-124, a brain expressed miRNA gene, no contribution to mesial temporal lobe epilepsy in an Italian sample. Neurol Sci 37(8):1335–1339CrossRefPubMedGoogle Scholar
  5. 5.
    Haerian BS, Baum L, Kwan P, Tan HJ, Raymond AA, Mohamed Z (2013) SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics 14(10):1153–1166CrossRefPubMedGoogle Scholar
  6. 6.
    Qian L, Fang S, Yan YL, Zeng SS, Xu ZJ, Gong ZC (2017) The ABCC2 c.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: a meta-analysis. J Clin Neurosci 37:6–14CrossRefPubMedGoogle Scholar
  7. 7.
    Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M (2010) Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 9(4):413–424CrossRefPubMedGoogle Scholar
  8. 8.
    Zuliani V, Fantini M, Rivara M (2012) Sodium channel blockers as therapeutic target for treating epilepsy: recent updates. Curr Top Med Chem 12(9):962–970CrossRefPubMedGoogle Scholar
  9. 9.
    Ferraro TN, Buono RJ (2005) The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav 7(1):18–36CrossRefPubMedGoogle Scholar
  10. 10.
    Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, Lui CHT, Sin NC, Wong KS, Baum L (2008) Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 18(11):989–998CrossRefPubMedGoogle Scholar
  11. 11.
    Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 102(15):5507–5512CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K (2008) Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol 66(2):304–307CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Abo El Fotoh WM et al (2016) The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children. Seizure 41:75–80CrossRefPubMedGoogle Scholar
  14. 14.
    Baghel R, Grover S, Kaur H, Jajodia A, Rawat C, Srivastava A, Kushwaha S, Agarwal R, Sharma S, Kukreti R (2016) Evaluating the role of genetic variants on first-line antiepileptic drug response in North India: significance of SCN1A and GABRA1 gene variants in phenytoin monotherapy and its serum drug levels. CNS Neurosci Ther 22(9):740–757CrossRefPubMedGoogle Scholar
  15. 15.
    Daci A, Beretta G, Vllasaliu D, Shala A, Govori V, Norata GD, Krasniqi S (2015) Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients. PLoS One 10(11):e0142408CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kumari R, Lakhan R, Kumar S, Garg RK, Misra UK, Kalita J, Mittal B (2013) SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. Biochimie 95(6):1350–1353CrossRefPubMedGoogle Scholar
  17. 17.
    Ma CL, Wu XY, Zheng J, Wu ZY, Hong Z, Zhong MK (2014) Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics 15(10):1323–1336CrossRefPubMedGoogle Scholar
  18. 18.
    Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, Beccaria F, Benna P, Campostrini R, Canevini MP, Condino F, Durisotti C, Elia M, Giallonardo AT, Iudice A, Labate A, la Neve A, Michelucci R, Muscas GC, Paravidino R, Zaccara G, Zucca C, Zara F, Perucca E (2011) A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52(5):e40–e44CrossRefPubMedGoogle Scholar
  19. 19.
    Sanchez MB et al (2010) Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 19(2):93–101CrossRefPubMedGoogle Scholar
  20. 20.
    Sterjev Z, Kiteva G, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska T, Nestorovska K, Matevska N, Trajkovik-Jolevska S, Dimovski A, Suturkova Lj (2012) Influence of the SCN1A IVS5N + 5 G>A Polymorphism on Therapy with Carbamazepine for Epilepsy. Balkan J Med Genet 15(1):19–24PubMedPubMedCentralGoogle Scholar
  21. 21.
    Wang P, Zhou Q, Sheng Y, Tang B, Liu Z, Zhou B (2014) Association between two functional SNPs of SCN1A gene and efficacy of carbamazepine monotherapy for focal seizures in Chinese Han epileptic patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban 39(5):433–441PubMedGoogle Scholar
  22. 22.
    Yun W, Zhang F, Hu C, Luo X, Xue P, Wang J, Ge Y, Meng H, Guo Y (2013) Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Res 107(3):231–237CrossRefPubMedGoogle Scholar
  23. 23.
    Zhou L, Cao Y, Long H, Long L, Xu L, Liu Z, Zhang Y, Xiao B (2015) ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population. Pharmazie 70(6):416–420PubMedGoogle Scholar
  24. 24.
    Loscher W et al (2009) The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50(1):1–23CrossRefPubMedGoogle Scholar
  25. 25.
    Zarcone D, Corbetta S (2017) Shared mechanisms of epilepsy, migraine and affective disorders. Neurol Sci 38(Suppl 1):73–76CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina

Personalised recommendations